Top

Published in:

01-07-2015 | Research

Altered MicroRNA Expression in Folliculotropic and Transformed Mycosis Fungoides

Authors: Dóra Marosvári, Vanda Téglási, Irén Csala, Márta Marschalkó, Csaba Bödör, Botond Timár, Judit Csomor, Judit Hársing, Lilla Reiniger

Published in: Pathology & Oncology Research | Issue 3/2015

Abstract

Mycosis fungoides (MF) is a common, indolent primary cutaneous T-cell lymphoma (CTCL), with rare, more aggressive variants, such as folliculotropic MF (FMF). A minority of the MF cases may undergo large cell transformation (T-MF) associated with poor prognosis. A selection of microRNAs (miRs) contribute to the pathogenesis and progression of classic MF, and may also be useful in differential diagnostics. However, the molecular background of FMF and the mechanisms involved in large cell transformation are obscure. We analyzed the expression of 11 miRs in 9 FMF and 7 T-MF cases. Three miRs, including miR-93-5p, miR-181a and miR-34a were significantly upregulated in both FMF and T-MF. FMF also showed overexpression of miR-155 and miR-223, while miR-181b and miR-326 were overexpressed in T-MF cases compared to controls. These results by identifying a number of differentially expressed microRNAs add further insight into the molecular pathogenesis of folliculotropic MF and large cell transformation of MF.

Swerdlow SH, International Agency for Research on Cancer., World Health Organization. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon, France: International Agency for Research on Cancer, 2008

Willemze R, Jaffe ES, Burg G et al (2005) WHO-EORTC classification for cutaneous lymphomas. Blood 105:3768–85CrossRefPubMed

Scarisbrick JJ, Kim YH, Whittaker SJ et al (2014) Prognostic factors, prognostic indices and staging in mycosis fungoides and sezary syndrome: where are we now? Br J Dermatol 170:1226–36CrossRefPubMed

Gerami P, Rosen S, Kuzel T, Boone SL, Guitart J (2008) Folliculotropic mycosis fungoides: an aggressive variant of cutaneous T-cell lymphoma. Arch Dermatol 144:738–46PubMed

Vergier B, de Muret A, Beylot-Barry M et al (2000) Transformation of mycosis fungoides: clinicopathological and prognostic features of 45 cases french study group of cutaneious lymphomas. Blood 95:2212–8PubMed

Benner MF, Jansen PM, Vermeer MH, Willemze R (2012) Prognostic factors in transformed mycosis fungoides: a retrospective analysis of 100 cases. Blood 119:1643–9CrossRefPubMed

Wong HK, Mishra A, Hake T, Porcu P (2011) Evolving insights in the pathogenesis and therapy of cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome). Br J Haematol 155:150–66CrossRefPubMedCentralPubMed

van Doorn R, Zoutman WH, Dijkman R et al (2005) Epigenetic profiling of cutaneous T-cell lymphoma: promoter hypermethylation of multiple tumor suppressor genes including BCL7a, PTPRG, and p73. J Clin Oncol 23:3886–96CrossRefPubMed

Garzon R, Croce CM (2008) MicroRNAs in normal and malignant hematopoiesis. Curr Opin Hematol 15:352–8CrossRefPubMed

10.

Calore F, Lovat F, Garofalo M (2013) Non-coding RNAs and cancer. Int J Mol Sci 14:17085–110CrossRefPubMedCentralPubMed

11.

van Kester MS, Ballabio E, Benner MF et al (2011) miRNA expression profiling of mycosis fungoides. Mol Oncol 5:273–80CrossRefPubMed

12.

Maj J, Jankowska-Konsur A, Sadakierska-Chudy A, Noga L, Reich A (2011) Altered microRNA expression in mycosis fungoides. Br J Dermatol 166:331–6CrossRef

13.

Ralfkiaer U, Hagedorn PH, Bangsgaard N et al (2011) Diagnostic microRNA profiling in cutaneous T-cell lymphoma (CTCL). Blood 118:5891–900CrossRefPubMedCentralPubMed

14.

Moyal L, Barzilai A, Gorovitz B et al (2013) miR-155 is involved in tumor progression of mycosis fungoides. Exp Dermatol 22:431–3CrossRefPubMed

15.

Contassot E, Kerl K, Roques S et al (2008) Resistance to FasL and tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in Sezary syndrome T-cells associated with impaired death receptor and FLICE-inhibitory protein expression. Blood 111:4780–7CrossRefPubMed

16.

Dereure O, Levi E, Vonderheid EC, Kadin ME (2002) Infrequent Fas mutations but no Bax or p53 mutations in early mycosis fungoides: a possible mechanism for the accumulation of malignant T lymphocytes in the skin. J Invest Dermatol 118:949–56CrossRefPubMed

17.

Wu J, Nihal M, Siddiqui J, Vonderheid EC, Wood GS (2009) Low FAS/CD95 expression by CTCL correlates with reduced sensitivity to apoptosis that can be restored by FAS upregulation. J Invest Dermatol 129:1165–73CrossRefPubMed

18.

Nielsen M, Kaestel CG, Eriksen KW et al (1999) Inhibition of constitutively activated Stat3 correlates with altered Bcl-2/Bax expression and induction of apoptosis in mycosis fungoides tumor cells. Leukemia 13:735–8CrossRefPubMed

19.

Sommer VH, Clemmensen OJ, Nielsen O et al (2004) In vivo activation of STAT3 in cutaneous T-cell lymphoma. Evidence for an antiapoptotic function of STAT3. Leukemia 18:1288–95CrossRefPubMed

20.

Mao X, Orchard G, Lillington DM et al (2004) BCL2 and JUNB abnormalities in primary cutaneous lymphomas. Br J Dermatol 151:546–56CrossRefPubMed

21.

Mao X, Orchard G, Mitchell TJ et al (2008) A genomic and expression study of AP-1 in primary cutaneous T-cell lymphoma: evidence for dysregulated expression of JUNB and JUND in MF and SS. J Cutan Pathol 35:899–910CrossRefPubMed

22.

Mao X, Lillington D, Scarisbrick JJ et al (2002) Molecular cytogenetic analysis of cutaneous T-cell lymphomas: identification of common genetic alterations in sezary syndrome and mycosis fungoides. Br J Dermatol 147:464–75CrossRefPubMed

23.

Benner MF, Ballabio E, van Kester MS et al (2012) Primary cutaneous anaplastic large cell lymphoma shows a distinct miRNA expression profile and reveals differences from tumor-stage mycosis fungoides. Exp Dermatol 21:632–4CrossRefPubMed

24.

Prochazkova M, Chevret E, Mainhaguiet G et al (2007) Common chromosomal abnormalities in mycosis fungoides transformation. Genes, Chromosom Cancer 46:828–38CrossRef

25.

Laharanne E, Chevret E, Idrissi Y et al (2010) CDKN2A-CDKN2B deletion defines an aggressive subset of cutaneous T-cell lymphoma. Mod Pathol 23:547–58CrossRefPubMed

26.

Manfe V, Biskup E, Rosbjerg A et al (2012) miR-122 regulates p53/Akt signalling and the chemotherapy-induced apoptosis in cutaneous T-cell lymphoma. PLoS One 7:e29541CrossRefPubMedCentralPubMed

27.

McGirt LY, Adams CM, Baerenwald DA, Zwerner JP, Zic JA, Eischen CM (2013) miR-223 regulates cell growth and targets proto-oncogenes in mycosis fungoides/cutaneous T-cell lymphoma. J Investi Dermatol 134:1101–7CrossRef

28.

Mi QS, Xu YP, Wang H, Qi RQ, Dong Z, Zhou L (2013) Deletion of microRNA miR-223 increases Langerhans cell cross-presentation. Int J Biochem Cell Biol 45:395–400CrossRefPubMedCentralPubMed

29.

Sotillo E, Laver T, Mellert H et al (2011) Myc overexpression brings out unexpected antiapoptotic effects of miR-34a. Oncogene 30:2587–94CrossRefPubMedCentralPubMed

30.

Rizzo M, Mariani L, Cavallini S, Simili M, Rainaldi G (2012) The over-expression of miR-34a fails to block DoHH2 lymphoma cell proliferation by reducing p53 via c-MYC down-regulation. Nucleic acid therapeutics 22:283–8PubMed

31.

Kanavaros P, Ioannidou D, Tzardi M et al (1994) Mycosis fungoides: expression of C-myc p62 p53, bcl-2 and PCNA proteins and absence of association with Epstein-Barr virus. Pathol Res Pract 190:767–74CrossRefPubMed

32.

Salgado R, Servitje O, Gallardo F et al (2010) Oligonucleotide array-CGH identifies genomic subgroups and prognostic markers for tumor stage mycosis fungoides. J invest Dermatol 130:1126–35CrossRefPubMed

33.

Fang L, Du WW, Yang W et al (2012) MiR-93 enhances angiogenesis and metastasis by targeting LATS2. Cell cycle (Georgetown. Tex 11:4352–65

34.

Xi Y, Formentini A, Chien M et al (2006) Prognostic values of microRNAs in colorectal cancer. Biomark Insights 2:113–21PubMed

35.

Mansueto G, Forzati F, Ferraro A et al (2010) Identification of a New pathway for tumor progression: MicroRNA-181b Up-regulation and CBX7 down-regulation by HMGA1 protein. Genes & cancer 1:210–24CrossRef

36.

Taylor MA, Sossey-Alaoui K, Thompson CL, Danielpour D, Schiemann WP (2013) TGF-beta upregulates miR-181a expression to promote breast cancer metastasis. J Clin Invest 123:150–63CrossRefPubMedCentralPubMed

37.

Fang L, Deng Z, Shatseva T et al (2010) MicroRNA miR-93 promotes tumor growth and angiogenesis by targeting integrin-beta8. Oncogene 30:806–21CrossRefPubMed

38.

Williams A, Henao-Mejia J, Harman CC, Flavell RA (2013) miR-181 and metabolic regulation in the immune system. Cold Spring Harb Symp Quant Biol 78:223–30CrossRefPubMed

39.

Hsu SD, Tseng YT, Shrestha S et al (2014) miRTarBase update 2014: an information resource for experimentally validated miRNA-target interactions. Nucleic Acids Res 42:D78–85CrossRefPubMedCentralPubMed

40.

Scarisbrick JJ, Woolford AJ, Russell-Jones R, Whittaker SJ (2000) Loss of heterozygosity on 10q and microsatellite instability in advanced stages of primary cutaneous T-cell lymphoma and possible association with homozygous deletion of PTEN. Blood 95:2937–42PubMed

41.

Katona TM, Smoller BR, Webb AL, Hattab EM, Khalil A, Hiatt KM (2013) Expression of PTEN in mycosis fungoides and correlation with loss of heterozygosity. Am J Dermatopathol 35:555–60CrossRefPubMed

Title: Altered MicroRNA Expression in Folliculotropic and Transformed Mycosis Fungoides
Authors: Dóra Marosvári
Vanda Téglási
Irén Csala
Márta Marschalkó
Csaba Bödör
Botond Timár
Judit Csomor
Judit Hársing
Lilla Reiniger
Publication date: 01-07-2015
Publisher: Springer Netherlands
Published in: Pathology & Oncology Research / Issue 3/2015
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-015-9897-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2015

Circulating Her-2/Neu Extracellular Domain in Breast Cancer Patients-Correlation with Prognosis and Clinicopathological Parameters Including Steroid Receptor, Her-2/Neu Receptor Coexpression

HMCN1, a cell polarity-related gene, is somatically mutated in gastric and colorectal cancers

Identification of Key Genes Associated with Colorectal Cancer Based on the Transcriptional Network

Mutation of HELLS, a Chromatin Remodeling Gene, Gastric and Colorectal Cancers

Evaluation of Antitumor Activity of Platelet Microbicidal Protein on the Model of Transplanted Breast Cancer in CBRB-Rb(8.17)1Iem Mice

Molecular Spectrum of Somatic EGFR and KRAS Gene Mutations in non Small Cell Lung Carcinoma: Determination of Frequency, Distribution Pattern and Identification of Novel Variations in Indian Patients

Keynote webinar | Spotlight on antibody–drug conjugates in cancer